Results 21 to 30 of about 8,085 (173)

Paraneoplastic neurologic syndromes

open access: yesAnnals of Oncology, 1995
Paraneoplastic neurologic syndromes (PNS) are remote, nonmetastatic complications of systemic cancer. Clinically they are characterized by subacute, progressive neurologic deficits that usually result in profound disability and eventually death. PNS may be present as long as 2 to 4 years before diagnosis of the associated tumor, but it can develop ...
J, Bauer, T, Kuntzer, S, Leyvraz
openaire   +2 more sources

Neurological paraneoplastic syndromes. [PDF]

open access: yesJournal of Clinical Pathology, 1997
Paraneoplastic neurological syndromes are uncommon, however, their diagnosis is of major practical importance. The identification of antibodies in the serum or cerebrospinal fluid in central nervous system paraneoplastic syndromes confirms the clinical diagnosis of a paraneoplastic syndrome and allows early identification of an underlying tumour at a ...
U, Nath, R, Grant
openaire   +2 more sources

Paraneoplastic endocrine-metabolic syndromes

open access: yesItalian Journal of Medicine, 2013
BACKGROUND The paraneoplastic syndromes (PS) are characterized by the presence of biochemical alterations, signs and symptoms expressive of cancer distance action into the patient’s organism.
Marco Grandi   +16 more
doaj   +1 more source

Comparison of commercial and in-house tissue-based and cell-based assays for the detection of autoantibodies targeting neuronal surface proteins: a prospective cohort study

open access: yesFrontiers in Immunology
IntroductionThe detection of antibodies targeting neuronal antigens is a keystone for the diagnosis of autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS).
David Goncalves   +17 more
doaj   +1 more source

Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer

open access: yesGynecologic Oncology Reports, 2017
Paraneoplastic syndromes are a group of rare disorders that can be triggered by an abnormal immune response to proteins from tumors of the lung, ovary, lymphatics, or breast. Paraneoplastic clinical syndromes affect
Madhumita Chatterjee   +2 more
doaj   +1 more source

Psychiatric manifestations of paraneoplastic syndromes

open access: yesEuropean Psychiatry, 2022
Introduction Paraneoplastic syndromes (PS) result from indirect effects of neoplasms. In 50% of the cases the symptoms precede the diagnosis and run independently.
M. Lemos, A. Lourenço, M. Ribeiro
doaj   +1 more source

A rare case of concomitant Lambert–Eaton myasthenic syndrome and syndrome of inappropriate antidiuretic hormone secretion in a patient with small cell lung carcinoma

open access: yesRespiratory Medicine Case Reports, 2023
Small cell lung carcinoma (SCLC) is a neuroendocrine carcinoma with a poor prognosis and is a common cause of paraneoplastic syndromes. Paraneoplastic syndromes are characterized by neurological and endocrinological problems in patients with malignancy ...
Yasuharu Oda   +9 more
doaj   +1 more source

Paraneoplastic syndromes associated with tumors of the digestive system

open access: yesUniversidad Médica Pinareña, 2021
Introduction: paraneoplastic syndromes are sets of signs and symptoms affecting cancer patients, which do not depend directly on the tumor. Objective: to describe paraneoplastic syndromes associated with digestive system tumors.
Roxana Vitón-Moreno   +1 more
doaj  

Paraneoplastic Neurologic Syndromes.

open access: yesInternal Medicine, 1996
Paraneoplastic neurologic syndromes are degenerative diseases of the central or peripheral nervous system that develop in association with a systemic neoplasm without a direct invasion by tumor. The pathogenesis of this disorder has been hypothesized in the past, and now there is increasing evidence that autoimmune processes triggered by the underlying
openaire   +5 more sources

Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes

open access: yesNeurología (English Edition), 2018
Objective: Analyse the clinical profile, associated tumour types, and response to treatment of paraneoplastic neurological syndromes associated with antibodies against Ma proteins.
G. Ortega Suero   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy